Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.
Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.
| Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Market | |
|---|---|---|---|---|---|---|
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
| India | U.S. |
Centhaquine (Lyfaquin®) is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock...
Read More
Septic shock is defined as a life-threatening organ dysfunction caused by a dysregulated host response to ...
Read More
Acute kidney injury (AKI) is a common complication in critically ill patients and is associated with increased...
Read More
An experimental study was performed using an established model of cardiac arrest. Cardiopulmonary...
Read More
Stroke is an important cause of serious long-lasting disability. Ischemic stroke caused by arterial occlusion...
Read More
Alzheimer’s disease is the sixth-leading cause of death in the United States. An estimated 5.3 million Americans...
Read More
It is now known that progenitor stem cells are present in the spinal cord.Exposure of cultured neural progenitor cells to hypoxia also...
Read More
The management team is well balanced with significant drug development and clinical expertise, and commercialization experience. In addition to the management and development team in the US, the company has over 80 employees through its subsidiary in India.
More Details
Dr. Gulati is leading clinical development and commercialization of first-in-class drug products in critical care medicine. He led the discovery, development and launch of Lyfaquin for hypovolemic shock.
Dr. McDonnell received his undergraduate degree from Georgetown University and his MD in 1985 from Northwestern University. Dr. McDonnell has also received postgraduate training in Emergency and Internal Medicine at Northwestern University.
Mr. Costello brings about 20 years of accounting, budgeting, audit preparation, reporting and financial modeling experience to Pharmazz. He served as Controller for Julian Toft and Downey, Inc. and as Vice President in Transwestern Commercial Real Estate’s
Dr. Gulati has more than 38 years of experience and knowledge in starting and running medium sized organizations. He is the founding member of Pharmazz India Private Limited and is managing and operating the company since its inception.
Mr. Stauder has more than 35 years of experience in the healthcare capital markets and investment banking industry. He has assisted biotechnology and life science companies in raising more than $20 billion in over 500 transaction during that time.
By EP News Bureau On Aug 2, 2023 -- Centhaquine, a first-in-class drug developed by Pharmazz India, a majority-owned subsidiary..
By BioSpectrum India On Aug 2, 2023 -- Pharmazz India, a majority-owned subsidiary of US-based Pharmazz, Inc.’s first-in-class
By Pharmabiz On Aug 2, 2023 -- Pharmazz India Private Limited, a majority-owned subsidiary of Pharmazz, Inc, has announced
